Clinical Trial Update: Study of Efficacy and Safety of MAS825 in Patients With COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of MAS825 for COVID-19 pneumonia with impaired respiratory function has completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia
• Impaired Respiratory Function Due to COVID-19

Drugs mentioned

• MAS825

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: COVID-19 Pneumonia, Impaired Respiratory Function | Phase 2 | Status: COMPLETED | Results posted: 2022-04-20